 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...4567891011121314...208209» |
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage III acral melanoma: Updated CAP 03-NEO trial results and external control comparison. (Hall A - Posters and Exhibits; Poster Bd #: 287) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2611;
P2
Clinical Trial Registration Number: NCT05512481 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- SHR-1501 / Jiangsu Hengrui Pharma
Updated efficacy and safety of SHR-1501, an IL-15R?Fc superagonist, with or without Bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study. (Hall A - Posters and Exhibits; Poster Bd #: 105) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2401;
P1/2
Funded by Jiangsu Hengrui Pharmaceuticals Co. Ltd Clinical Trial Registration Number: NCT05410730 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Neoadjuvant apatinib plus camrelizumab in renal cell carcinoma with inferior vena cava tumor thrombus: Results of a phase II study. (Hall A - Posters and Exhibits; Poster Bd #: 15) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2379;
P1
Ltd Clinical Trial Registration Number: NCT05410730 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by National Natural Science Foundation of China Natural Science Foundation of Beijing Municipality Clinical Trial Registration Number: ChiCTR2300069990 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Efficacy and safety of camrelizumab combined with docetaxel and carboplatin as neoadjuvant therapy for triple-negative breast cancer: The HELEN-Trio 011 randomized clinical trial. (Hall B1) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2325;
P2
Funded by National Natural Science Foundation of China Natural Science Foundation of Beijing Municipality Clinical Trial Registration Number: ChiCTR2300069990 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT05475678 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
Rezvilutamide (Rez) versus bicalutamide (Bic) plus androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): 5-year outcomes of the phase 3 CHART trial. (Hall A - Posters and Exhibits; Poster Bd #: 185) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2310;
P3
Funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Clinical Trial Registration Number: NCT03520478 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- M9466 / EMD Serono
Safety and preliminary efficacy of M9466 (HRS-1167) in combination with abiraterone acetate and prednisone/prednisolone (AA-P) in patients (pts) with metastatic prostate cancer in the phase 1 DDRiver 501 study. (Hall A - Posters and Exhibits; Poster Bd #: 133) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2276;
P1
Clinical Trial Registration Number: NCT03520478 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945) Clinical Trial Registration Number: NCT06421935 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- M9466 / EMD Serono
HRS-1167 (M9466), a PARP1 inhibitor, combined with abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: A phase 1b/2 study. (Hall A - Posters and Exhibits; Poster Bd #: 131) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2245;
P1/2
Funded by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945) Clinical Trial Registration Number: NCT06421935 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Jiangsu Hengrui Pharmaceuticals Clinical Trial Registration Number: NCT06689163 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
An open-label, parallel-cohort, multicenter clinical study of rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer. (Hall A - Posters and Exhibits; Poster Bd #: 234b) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2208;
P4
Funded by Jiangsu Hengrui Pharmaceuticals Clinical Trial Registration Number: NCT06689163 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by the Development Center for Medical Science & Technology National Health Commission Clinical Research Project Clinical Trial Registration Number: ChiCTR2400093262 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- fosrolapitant/palonosetron (HR20013) / Jiangsu Hengrui Pharma
Randomized, double-blind phase 3 trial of the fixed-dose combination fosrolapitant/palonosetron (HR20013) plus dexamethasone for prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. (S100bc) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2138;
P3
Funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Clinical Trial Registration Number: NCT06554184 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Phase 3 trial of trastuzumab rezetecan vs standard of care (SOC) for chemotherapy-refractory, HER2-positive, advanced colorectal cancer (CRC). (Hall D2) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2124;
P3
Funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Clinical Trial Registration Number: NCT06199973 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Itari (linperlisib) / Shanghai YingLi Pharma
Linperlisib plus CHOP for newly diagnosed peripheral T-cell lymphoma: A single-arm, phase Ib/II study (LINCH trial). (Arie Crown Theater) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2086;
P1/2
Clinical Trial Registration Number: NCT06199973 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT05949944 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Fuzuloparib combined with abiraterone acetate and prednisone (AA-P) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Interim results from the FUZUPRO trial. (Hall D1) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2055;
P3
Clinical Trial Registration Number: NCT05949944 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Jiangsu Hengrui Pharmaceuticals Clinical Trial Registration Number: NCT04691804 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
A prospective, single-arm, phase II exploratory clinical study on the efficacy and safety of neoadjuvant adebrelimab combined with cisplatin and docetaxel in patients with clinical stage IVB oral squamous cell carcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 505) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2031;
P2
Funded by Jiangsu Hengrui Pharmaceuticals Clinical Trial Registration Number: NCT04691804 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06277791 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Erbitux (cetuximab) / Eli Lilly, AiRuiKa (camrelizumab) / Elevar Therapeutics
Neoadjuvant therapy for head and neck squamous cell carcinoma based on hyperprogression genotyping: Cetuximab beta combined with chemotherapy with or without camrelizumab. (Hall A - Posters and Exhibits; Poster Bd #: 589a) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1969;
P=N/A
Clinical Trial Registration Number: NCT06277791 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2500108701 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Neoadjuvant adebrelimab plus chemotherapy in untreated locally advanced head and neck squamous cell carcinoma: Efficacy and biomarker insights from a single-arm phase 2 trial. (Hall A - Posters and Exhibits; Poster Bd #: 563) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1963;
P2
Clinical Trial Registration Number: ChiCTR2500108701 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by National Natural Science Foundation of China Clinical Trial Registration Number: ChiCTR2400091171 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Induction adebrelimab combined with chemotherapy followed by response-adaptive concurrent chemoradiotherapy guided by PET-CT in locally advanced unresectable esophageal squamous cell carcinoma: A prospective, single-arm, phase II study. (Hall A - Posters and Exhibits; Poster Bd #: 468b) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1874;
P2
Funded by National Natural Science Foundation of China Clinical Trial Registration Number: ChiCTR2400091171 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT07112833 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Hetrombopag in patients with chemotherapy-induced thrombocytopenia: A global phase 3, randomized, double-blind study. (Hall A - Posters and Exhibits; Poster Bd #: 144b) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1705;
P3
Clinical Trial Registration Number: NCT07112833 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Jiangsu Hengrui Pharmaceuticals Clinical Trial Registration Number: NCT07286032 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Hetrombopag plus caffeic acid tablets for the treatment of chemotherapy-induced thrombocytopenia in solid tumors: A single-center, open-label, phase II trial. (Hall A - Posters and Exhibits; Poster Bd #: 113) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1637;
P=N/A
Funded by Jiangsu Hengrui Pharmaceuticals Clinical Trial Registration Number: NCT07286032 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2400086043 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
DEB-TACE combined with apatinib and camrelizumab as second-line therapy for unresectable intrahepatic cholangiocarcinoma: A prospective, single-arm, phase II study. (Hall A - Posters and Exhibits; Poster Bd #: 147) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1577;
P2
Clinical Trial Registration Number: ChiCTR2400086043 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT04834674 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Phase Ib/II clinical study of adebrelimab combined with decitabine, nab-paclitaxel, and gemcitabine as first-line (IL) treatment for metastatic pancreatic cancer (mPC). (Hall A - Posters and Exhibits; Poster Bd #: 183) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1547;
P1/2
Clinical Trial Registration Number: NCT04834674 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Tianjin Science and Technology Commission key project Clinical Trial Registration Number: NCT06454448 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
A prospective single-arm study of irinotecan liposome II combined with adebrelimab, gemcitabine, and nab-paclitaxel for conversion therapy in locally advanced pancreatic cancer. (Hall A - Posters and Exhibits; Poster Bd #: 235a) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1499;
P2
Funded by Tianjin Science and Technology Commission key project Clinical Trial Registration Number: NCT06454448 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2500108269 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- SHR-A2102 / Jiangsu Hengrui Pharma, HRS-4642 / Jiangsu Hengrui Pharma
SHR-A2102, a Nectin-4 targeted antibody-drug conjugate, combined with HRS-4642 in previously treated pancreatic ductal adenocarcinoma harboring KRAS G12D mutation. (Hall A - Posters and Exhibits; Poster Bd #: 174) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1470;
P2
Clinical Trial Registration Number: ChiCTR2500108269 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06547736 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- RGL-270 / Shanghai Regenelead Therapies, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Safety, efficacy, and immunogenicity of adjuvant therapy with personalized cancer vaccine (PCV) RGL-270 in combination with adebrelimab and mFOLFIRINOX in resectable pancreatic ductal adenocarcinoma (PDAC). (Hall A - Posters and Exhibits; Poster Bd #: 214) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1467;
P1
Clinical Trial Registration Number: NCT06547736 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0525500/2024ZD0525505) Clinical Trial Registration Number: NCT06156267 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Neoadjuvant adebrelimab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: A single-arm, phase II trial. (Hall A - Posters and Exhibits; Poster Bd #: 73) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1424;
P2
Funded by Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0525500/2024ZD0525505) Clinical Trial Registration Number: NCT06156267 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2400085858 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
NALIRIFOX in combination with adebrelimab for advanced biliary tract cancer: A phase 2 NIOFA-01 clinical trial. (Hall A - Posters and Exhibits; Poster Bd #: 103) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1423;
P2
Clinical Trial Registration Number: ChiCTR2400085858 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2400089696 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): Long-term outcomes of a single-arm phase II trial. (Hall A - Posters and Exhibits; Poster Bd #: 42) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1413;
P2
Clinical Trial Registration Number: ChiCTR2400089696 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2000034304 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, HRS-4642 / Jiangsu Hengrui Pharma
HRS-4642 combined with adebrelimab in previously treated patients with metastatic pancreatic ductal adenocarcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 173) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1406;
P1/2
Clinical Trial Registration Number: ChiCTR2000034304 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06427239 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
CAREFOL: A phase 3, randomized, open-label, multicenter trial of camrelizumab and rivoceranib with or without intravenous FOLFOX chemotherapy as first-line treatment for unresectable hepatocellular carcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 231a) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1359;
P3
Clinical Trial Registration Number: NCT06427239 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT07267806 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKa (camrelizumab) / Elevar Therapeutics, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A phase II study of bTAE-HAIC combined with lenvatinib and camrelizumab for patients with high tumor burden hepatocellular carcinoma: The TALEM-H trial. (Hall A - Posters and Exhibits; Poster Bd #: 106) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1345;
P=N/A
Clinical Trial Registration Number: NCT07267806 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06061276 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
A multicenter single-arm study of induction EC/EP plus camrelizumab followed by maintenance camrelizumab plus apatinib in treatment-naive advanced or metastatic extrapulmonary neuroendocrine carcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 159) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1338;
P2
Clinical Trial Registration Number: NCT06061276 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Natural Science Foundation of Hubei Province of China Clinical Trial Registration Number: NCT05142865 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
The CONVERGE study: A phase II, single-arm trial of adebelimab combined with targeted therapy and liposomal irinotecan-based chemotherapy for conversion surgery in unresectable MSS colorectal cancer liver metastases. (Hall A - Posters and Exhibits; Poster Bd #: 371) - Apr 21, 2026 - Abstract #ASCO2026ASCO_896;
P2
Funded by Natural Science Foundation of Hubei Province of China Clinical Trial Registration Number: NCT05142865 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Hengrui Pharma Clinical Trial Registration Number: ChiCTR2600117031 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
SHR-A1811 plus chemotherapy and BP102 as 1L therapy for HER2-expressing mCRC: Data from a phase Ib/II study. (Hall A - Posters and Exhibits; Poster Bd #: 336) - Apr 21, 2026 - Abstract #ASCO2026ASCO_888;
P1/2
Funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Clinical Trial Registration Number: NCT06015048 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- SHR-A2102 / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Perioperative SHR-A2102, a novel nectin-4 (Arie Crown Theater) - Apr 21, 2026 - Abstract #ASCO2026ASCO_724;
P2/3
Funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Clinical Trial Registration Number: NCT06879145 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- | cisplatin / Generic mfg., AiRuiKa (camrelizumab) / Elevar Therapeutics, albumin-bound paclitaxel / Generic mfg.
Journal: Comprehensive treatment for intracranial invasive sinonasal intestinal-type adenocarcinoma with a focus on radiotherapy dosage and immunological combination therapy: A case report. (Pubmed Central) - Apr 21, 2026
On the whole, the present case report highlights the need for sufficient radiotherapy (?66 Gy EQD2) for ITAC in complex anatomical areas, highlighting the role of advanced techniques to overcome dose limitations. Moreover, the 'chemo-immuno induction plus immuno-maintenance' approach in PD-L1-positive patients exhibits potential for long-term disease control, providing a novel treatment model for advanced-stage ITAC.
- | Journal: Laparoscopic Extended Left Hepatectomy and Portal Vein Thrombectomy for Advanced Hepatocellular Carcinoma After Second-Line Conversion Therapy. (Pubmed Central) - Apr 21, 2026
This case report highlights that, for patients with HCC-PVTT with first-line therapy resistance, actively applying second-line therapy can still yield an opportunity for radical resection. It also suggests the feasibility of laparoscopic extended hepatectomy with thrombectomy, emphasizing the value of individualized, multidisciplinary strategies for improving outcomes in complex HCC cases.
- | ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment open: Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes (clinicaltrials.gov) - Apr 21, 2026
P2, N=250, Recruiting, Sponsor: Kailera
It also suggests the feasibility of laparoscopic extended hepatectomy with thrombectomy, emphasizing the value of individualized, multidisciplinary strategies for improving outcomes in complex HCC cases. Not yet recruiting --> Recruiting
- ||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
P3 data, Retrospective data, Journal: Efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis: a post-hoc exploratory analysis of a phase III trial. (Pubmed Central) - Apr 19, 2026
P3
The incidence of any adverse events was not different between super responders and non-super responders (all P?>?0.05). After vunakizumab treatment, super responder status is associated with better treatment response and PROs in patients with moderate-to-severe plaque psoriasis, while the safety is not affected by this status.
- | Trial completion, Enrollment change, Trial completion date: CHANCE2202: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC (clinicaltrials.gov) - Apr 17, 2026
P=N/A, N=941, Completed, Sponsor: Zhongda Hospital
After vunakizumab treatment, super responder status is associated with better treatment response and PROs in patients with moderate-to-severe plaque psoriasis, while the safety is not affected by this status. Recruiting --> Completed | N=220 --> 941 | Trial completion date: Sep 2023 --> Sep 2025
- | New trial: Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment (clinicaltrials.gov) - Apr 17, 2026
P=N/A, N=200, Completed, Sponsor: Sun Yat-sen University
- | Trial completion, Enrollment change: CHANCE2201: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC (clinicaltrials.gov) - Apr 17, 2026
P=N/A, N=1244, Completed, Sponsor: Zhongda Hospital
Recruiting --> Completed | N=220 --> 941 | Trial completion date: Sep 2023 --> Sep 2025 Recruiting --> Completed | N=474 --> 1244
- || P2 data, Journal: Rezvilutamide plus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer patients after progression on abiraterone: A multi-centre, open-label, phase II trial. (Pubmed Central) - Apr 16, 2026
Recruiting --> Completed | N=474 --> 1244 Rezvilutamide plus docetaxel followed by maintenance with rezvilutamide monotherapy demonstrated good tolerability and promising efficacy in chemotherapy-naive, abiraterone-refractory, mCRPC patients.
- ||||| sonesitatug vedotin (AZD0901) / AstraZeneca
Enrollment closed, Monotherapy: CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov) - Apr 15, 2026
P3, N=572, Active, not recruiting, Sponsor: AstraZeneca
Rezvilutamide plus docetaxel followed by maintenance with rezvilutamide monotherapy demonstrated good tolerability and promising efficacy in chemotherapy-naive, abiraterone-refractory, mCRPC patients. Recruiting --> Active, not recruiting
- || HRS-7535 / Kailera Therapeutics
Trial completion: A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects (clinicaltrials.gov) - Apr 15, 2026
P1, N=40, Completed, Sponsor: Shandong Suncadia Medicine Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
New P2 trial: STELLAR01: Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 15, 2026
P2, N=98, Recruiting, Sponsor: Ning Jiang, M.D./Ph.D.
- |||| Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
New P2 trial: Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. (clinicaltrials.gov) - Apr 14, 2026
P2, N=100, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- |||||||||| HRS-7535 / Kailera Therapeutics
New P3 trial: Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity (clinicaltrials.gov) - Apr 14, 2026
P3, N=648, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: Clinical Study on the Effect of Tegileridine on Postoperative Pain in Patients Undergoing Abdominal Surgery. (clinicaltrials.gov) - Apr 14, 2026
P4, N=150, Completed, Sponsor: Xin Chen
Recruiting --> Completed Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
- | AiRuiKa (camrelizumab) / Elevar Therapeutics, Onivyde (nanoliposomal irinotecan) / Ipsen
New P2 trial, pMMR: Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer (clinicaltrials.gov) - Apr 14, 2026
P2, N=44, Not yet recruiting, Sponsor: Guangdong Provincial People's Hospital
- || retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
New P2 trial: SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy (clinicaltrials.gov) - Apr 13, 2026
P2, N=33, Not yet recruiting, Sponsor: Zhigang Li
- ||| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Clinical, P3 data, Journal: Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial. (Pubmed Central) - Apr 13, 2026
P3
Once-daily hetrombopag improved platelet responses, reduced rescue therapy use, and provided durable platelet control with an acceptable safety profile in children and adolescents with ITP. These findings support hetrombopag as an additional oral TPO-RA option for patients with inadequate response or relapse after first-line therapy.